| Nov 6 |
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
|
| Nov 6 |
BeiGene to Present at the Jefferies London Healthcare Conference
|
| Nov 5 |
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
|
| Oct 28 |
BeiGene Mourns Death of Beloved Board Member Donald Glazer
|
| Oct 25 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 22 |
Top Midday Gainers
|
| Oct 22 |
Indaptus Therapeutics signs clinical supply agreement with BeiGene
|
| Oct 21 |
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
|
| Oct 17 |
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years
|
| Oct 16 |
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
|
